title: [Effect of treatment with selective serotonin reuptake inhibitors on lipid profile: state of the art].
abstract: Selective Serotonin Reuptake Inhibitors (SSRI) are an effective treatment for depressive disorder. Nevertheless, there is evidence suggesting a negative effect of these drugs on the lipid profile of the patients. We carried out a systematic review of the literature evaluating the influence of therapy with SSRI on lipid profile. Data source was MEDLINE. Clinical trials, prospective studies, retrospective studies and reviews published until November 2011 were considered. We identified twelve studies published from 1994 to 2011, of which four were randomized clinical trials, six were prospective studies and two were retrospective studies. Sertraline and Paroxetine seemed to have negative effects on the serum levels of Total and LDL Cholesterol. Citalopram did not demonstrate any influence on Total and LDL Cholesterol blood levels, being conversely associated with a slight increase of the HDL Cholesterol levels. Few data were found about the effects of Fluoxetina e Fluvoxamina on lipid profile and no data were found about Escitalopram. Sertaline and Paroxetine, two effective and widely used drugs for the treatment of major depression, seem to have a negative effect on the lipid profile; Citalopram, with its neutral or positive effect on lipid profile, should be considered the treatment of choice for depressive patients affected by dyslipidemia.
authors.affiliation: Dipartimento di Medicina Interna e Specialità Mediche, Policlinico Umberto 1, Università di Roma Sapienza, Roma, Italia. m.colotto@policlinicoumberto1.it
authors.forename: M
authors.initials: M
authors.lastname: Colotto
authors.forename: F
authors.initials: F
authors.lastname: Vinci
authors.forename: N
authors.initials: N
authors.lastname: Vo Hong
authors.forename: O
authors.initials: O
authors.lastname: Raimo
authors.forename: A
authors.initials: A
authors.lastname: Castello
authors.forename: A
authors.initials: A
authors.lastname: Carnovale
authors.forename: A
authors.initials: A
authors.lastname: Paciaroni
authors.forename: P
authors.initials: P
authors.lastname: Coletta
mesh_terms: D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015283:Citalopram / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D003863:Depression / Q000097:blood / Q000188:drug therapy; D003866:Depressive Disorder / Q000097:blood / Q000188:drug therapy; D004311:Double-Blind Method; D050171:Dyslipidemias / Q000139:chemically induced* / Q000517:prevention & control; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D011446:Prospective Studies; D016032:Randomized Controlled Trials as Topic; D012189:Retrospective Studies; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D015283:Citalopram; D017367:Selective Serotonin Reuptake Inhibitors